Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35211290 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2POLBLMNAGBA2MAPT | |
| SCHEMBL16090883 | 0.87 | TSHR (0.47) | SMN1; SMN2POLBLMNAMAPTRAB9A | |
| Hydrochloric Acid SCHEMBL30567869 | 0.86 | TSHR (0.46) | SMN1; SMN2POLBLMNAMAPTRAB9A | |
| SCHEMBL1439521 | 0.82 | LMNA (0.49) | SMN1; SMN2POLBLMNAGBA2MAPT | |
| SCHEMBL12870626 | 0.81 | SMN1; SMN2 (0.54) | SMN1; SMN2POLBLMNAGBA2MAPT | |
| SCHEMBL3938079 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2POLBLMNAGBA2MAPT | |
| SCHEMBL3939212 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2POLBLMNAGBA2MAPT | |
| SCHEMBL19757289 | 0.80 | PDK1 (0.43) | SMN1; SMN2LMNAPDK1TSHRPDK2 | |
| SCHEMBL3712797 | 0.80 | SMN1; SMN2 (0.55) | SMN1; SMN2POLBLMNAGBA2MAPT | |
| SCHEMBL28194933 | 0.80 | POLB (0.55) | SMN1; SMN2POLBLMNAGBA2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283361-B2 | Heterocyclic urea derivatives and methods of use thereof | ASTRAZENECA AB (SE) | 2012-10-09 | — | — | US | disclosed |
| US-20100190745-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190745-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | UROD, UMPS, SLC14A1 | SMN1; SMN2 3620/4885POLB 831/4885LMNA 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.